Immodulon Therapeutics Ltd

Quick facts

Phase 3 pipeline

• IMM-101 · Oncology
  IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.

Phase 2 pipeline

• Mycobacterium obuense

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immodulon Therapeutics Ltd portfolio CI brief
• Immodulon Therapeutics Ltd pipeline updates RSS